Cantor Fitzgerald, L. P. Denali Therapeutics Inc. Transaction History
Cantor Fitzgerald, L. P.
- $8.4 Billion
- Q3 2025
A detailed history of Cantor Fitzgerald, L. P. transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Cantor Fitzgerald, L. P. holds 45,000 shares of DNLI stock, worth $784,800. This represents 0.01% of its overall portfolio holdings.
Number of Shares
45,000
Previous 45,000
-0.0%
Holding current value
$784,800
Previous $653,000
-0.0%
% of portfolio
0.01%
Previous 0.01%
Shares
1 transactions
Others Institutions Holding DNLI
# of Institutions
259Shares Held
133MCall Options Held
219KPut Options Held
107K-
Black Rock Inc. New York, NY13.2MShares$230 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$209 Million0.0% of portfolio
-
Baillie Gifford & CO11.6MShares$202 Million0.13% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.64MShares$98.3 Million0.05% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL5.47MShares$95.3 Million0.02% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $2.34B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...